Estriol vs Estradiol: Which Estrogen Does What

The Short Answer

The Short Answer on Estriol vs Estradiol

The short answer on estriol vs estradiol is that estradiol is the potent estrogen FDA-approved menopause therapy is built on, and estriol is the weak one that reaches patients in the United States only through compounding.

Both are human estrogens, so the difference is one of degree and of paperwork. Your ovaries make mostly estradiol during your reproductive years, while the placenta makes large amounts of estriol during pregnancy. After menopause the ovaries largely stop, but estrogen production does not end: fat, skin and other tissues convert adrenal androgens into estrone and then estradiol, which is why a postmenopausal woman still has circulating estrogen and why higher body fat raises it.

The practical consequence is that the short answer on estriol vs estradiol is rarely settled by pharmacology. It is settled by what a physician can prescribe at a dose she can stand behind.

Potency

How Potent Is Estriol Compared With Estradiol?

Of the three main human estrogens, estradiol, estrone and estriol, estriol is the weakest and estradiol the most potent, so estriol compared with estradiol needs more drug on board to do the same work at the receptor.

Estrogens act by binding estrogen receptors. Estradiol binds the estrogen receptor with high affinity and stays bound long enough to drive a full response. Estriol binds more weakly and lets go faster, and that short occupancy is the mechanism behind its reputation as a gentle estrogen.

So potency is real, and it is a dial rather than a safety category. Estriol is less potent than estradiol, not a different class of drug, and the physician writing the prescription sets the dial.

FDA Status

Is Estriol FDA-Approved in the United States?

Estriol is not FDA-approved in the United States, and the agency states the point without hedging: there are no FDA-approved drugs containing estriol.

On its menopause page the FDA writes that marketed drugs containing estriol are compounded drugs, which are not FDA-approved, and that it does not have evidence that drugs containing estriol are safe and effective, or are safer forms of estrogen. That is not a finding that estriol is dangerous. It is a statement that the trials which would let the agency say either way have not been submitted.

Compounding itself is legal and often useful. A compounding pharmacy can produce a strength or base no manufacturer sells, which is a real service for a patient who reacts to an excipient. What compounding cannot supply is an FDA-reviewed label, a verified potency and a tested shelf life.

Estriol is therefore obtainable in the United States only through compounding and never as an FDA-approved drug, and those three missing assurances are what you accept when you buy one. That tradeoff belongs in the consultation, before a prescription is written rather than after.

Approved Forms

Which FDA-Approved Estradiol Products Exist?

FDA-approved estradiol products exist across most routes a patient might want, and that range is the real practical gap between estradiol and estriol.

• Oral tablets, swallowed daily.
• Transdermal patches, worn on the skin and replaced on a schedule.
• Topical gels, emulsions and sprays.
• Vaginal creams, tablets, inserts and rings, acting mainly where placed.

Every one of those forms carries an approved label stating a strength, a frequency and a list of warnings. That is why a physician can move you from a pill to a patch and know what the new number means, and why federal label work reaches these products and not compounded estriol.

On November 10, 2025 the FDA announced that it was initiating removal of the boxed-warning references to cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products, and on February 12, 2026 it approved the first six revised labels. The endometrial-cancer boxed warning on systemic estrogen-alone products remains. We covered that change in the FDA's removal of the HRT black box warning.

FDA-approved estradiol products matter here not for prestige but because a reviewed label lets a physician prescribe to a known number rather than to a hope.

The Trial

What a Head-to-Head Trial of Estradiol and Estriol Found

A head-to-head trial of estradiol and estriol found that both relieved vaginal atrophy, and what separated them was not symptom relief at all.

In a 2000 study in Acta Obstetricia et Gynecologica Scandinavica, 96 postmenopausal women with atrophic vaginitis were treated for 24 weeks with either estradiol vaginal tablets or estriol vagitories. Both groups improved significantly on itching, irritation, dryness and pain with sex. The regimen the trial used was daily for the first two weeks and twice weekly thereafter, in both arms. That is what the investigators did, not a schedule to copy; your own frequency is set by the prescribing physician.

What the trial actually measured as a difference was tolerability. Among the women on estriol vagitories, 31 of them, 65 percent, reported leakage, and 14, 29 percent, needed sanitary protection. In the estradiol vaginal tablet group three women, 6 percent, reported leakage and none needed protection. Ninety percent of the tablet group called the medication hygienic against 79 percent on estriol, and 49 percent called the product easy to use against 28 percent. Endometrial thickness rose over the first two weeks in both arms, by 1.1 mm on the estradiol tablet against 0.5 mm on the estriol vagitory, and returned to baseline once application dropped to twice weekly. The abstract is on PubMed.

Two limitations deserve naming. It is a single trial, and it ran 24 weeks on two specific products rather than on two molecules in the abstract.

Still, this head-to-head trial of estradiol and estriol found the tiebreaker clinical arguments usually miss, which is whether a woman keeps using the product she was given.

Vaginal Symptoms

Estriol vs Estradiol for Vaginal Symptoms

For vaginal symptoms, estriol vs estradiol is mostly a question of which product comes with a known dose, and vaginal estradiol is the one that does.

The symptoms here are dryness, burning, irritation, pain with sex and urinary urgency, and they follow estrogen loss in vulvar, vaginal and urethral tissue. Local estrogen acts where it is applied and produces very low systemic levels at low doses, which is why its risk conversation differs from the one for pills and patches. Protocol Health's vaginal estrogen option is that local route, and its estrogen cream and gel option is the topical one.

Compounded estriol vaginal cream exists and some women prefer it. The case for it is that estriol is weak, so a woman wary of estrogen feels she is taking a smaller step. The case against it is that weakness is not absence, no approved estriol product exists to anchor the strength, and the one head-to-head trial found the estradiol tablet easier to live with.

For vaginal symptoms, either molecule can relieve the tissue, and estriol vs estradiol is decided on dose certainty rather than on a claim that estriol does nothing.

Face and Skin

Estriol vs Estradiol for the Face and Skin

For the face and skin, estriol vs estradiol is a marketing contest more than a clinical one, because no estriol face product is FDA-approved and estradiol is not approved for cosmetic use either.

The underlying biology is not in dispute. Estrogen receptors are present in skin, and the fall in estrogen at menopause tracks with thinner skin, less collagen and more dryness. What does not follow is that a compounded estriol cream on the face has been shown in adequate trials to change any of it. The FDA's position that it lacks evidence estriol products are safe and effective applies to a face cream exactly as to a vaginal cream.

There is a practical point underneath the cosmetic one. Estrogen applied to facial skin is absorbed, and absorbed estrogen is systemic estrogen. A woman already on hormone therapy is stacking doses without a number.

On the face and skin, both estriol and estradiol are used outside an approved indication, so the evidence is thin either way and anything hormonal on your face belongs in the same consultation as the rest of your hormone plan.

Bi-Est

Bi-Est and Tri-Est: Compounded Estriol and Estradiol Blends

Bi-Est and Tri-Est are compounded blends of estriol and estradiol, and neither is an FDA-approved product.

Compounding pharmacies most often prepare Bi-Est at a ratio of 80 percent estriol to 20 percent estradiol, and Tri-Est adds estrone. The pitch is that this mirrors the estrogen proportions of a premenopausal woman. The flaw is that a premenopausal woman does not absorb estriol from a cream; she makes estradiol in her ovaries and her body converts it. Copying a blood ratio with a topical product does not copy the physiology behind it, and the ratio you receive is the compounder's, confirmed by the prescribing physician rather than by a label.

None of which makes Bi-Est illegitimate. Some women land on a compounded blend for real reasons of sensitivity, and a good physician will say so. The same physician should also say that the FDA has not reviewed the blend and that the endometrial question does not evaporate because most of the mixture is weak. Our longer treatment sits in bioidentical vs synthetic hormones.

A Bi-Est or Tri-Est preparation is therefore a compounded estriol and estradiol blend chosen for preference and tolerance, not because an approval stands behind it.

Risks

Risks and Side Effects of Estriol and Estradiol

The risks and side effects of estriol and estradiol overlap heavily, because both are estrogens acting on the same receptors.

• Breast tenderness, nausea, headache, fluid retention and mood change are common on either.
• Unscheduled vaginal bleeding needs evaluation, because estrogen can thicken the uterine lining.
• Endometrial risk is why a woman with a uterus on systemic estrogen is generally prescribed a progestogen with it, and why the FDA kept the endometrial-cancer boxed warning on systemic estrogen-alone products.
• Clot risk tracks the route more than the molecule. Oral estrogen passes through the liver first and raises clotting factors in a way transdermal estrogen largely does not.
• Compounded products carry one risk approved ones do not: the strength you receive depends on a pharmacy's process, not an approved standard.

Benefits deserve the same weight. FDA-approved estrogen therapy is labeled for hot flashes and night sweats, for genitourinary symptoms, and for preventing bone loss after menopause. The 2025 and 2026 label changes reflect a judgment that a blanket boxed warning overstated the risk for symptomatic menopausal women. None of that makes estrogen risk-free, and none of it transfers to a product no regulator has reviewed.

So the risks and side effects of estriol and estradiol are the risks of estrogen, with one extra layer of uncertainty attached to anything compounded.

Candidacy

Who Should Not Use Estriol or Estradiol?

Who should not use estriol or estradiol is a prescribing physician's call, and several histories either take estrogen off the table or change how it is given.

• A current or past estrogen-sensitive breast cancer, or another estrogen-dependent tumor.
• Unexplained vaginal bleeding not yet worked up.
• Blood clots in the legs or lungs, or a clotting disorder.
• A past stroke or heart attack.
• Active liver disease.
• Pregnancy, or any chance of it.

That list opens a conversation rather than closing one. Some histories rule estrogen out altogether, some only move the route from a pill to a patch, and some apply to systemic therapy while leaving low-dose local therapy available after a specialist discussion.

Deciding who should not use estriol or estradiol takes a physician reading your actual records, and that is the part no article can do for you.

Our Approach

Estriol vs Estradiol at Protocol Health

At Protocol Health the estriol vs estradiol decision is made inside a visit, from labs and history, by the physician who signs the prescription.

The commercial part goes first. Protocol Health prescribes estrogen therapy and is paid for the assessments, labs and medication plans described here, so we have a financial interest in a woman deciding hormone therapy is worth discussing. We would rather disclose that than let you find it out later.

A visit is unglamorous. You come in or join by telehealth, we take a history, we run labs, and the physician decides whether estrogen is appropriate at all, then which molecule, which route, and whether a progestogen belongs with it. If you are already using a compounded estriol product, or are set on one, bring it to the visit so it can be reviewed against the FDA-approved options; what is prescribed in any given case is the physician's call after an evaluation.

In-person care happens in one place: 700 White Plains Rd #30, Scarsdale, NY 10583, at (914) 415-5546. Telehealth is open to eligible patients in New York, New Jersey, Connecticut, Florida and California. Protocol Health is family-owned and physician-led, and care in both settings is delivered by licensed Protocol Health clinicians.

The estriol vs estradiol question at Protocol Health gets settled where every prescribing question should, in a consultation rather than a comparison table. You can start with the hormone quiz.

FAQ

Frequently Asked Questions

Explore

Related at Protocol Health

• Estrogen Cream and Gel →
• Vaginal Estrogen →
• HRT for Women →
• Estrogen Patch vs Pill →